nodes	percent_of_prediction	percent_of_DWPC	metapath
Letrozole—CYP3A4—Cytarabine—lymphatic system cancer	0.0868	0.318	CbGbCtD
Letrozole—CYP3A4—Teniposide—lymphatic system cancer	0.0855	0.313	CbGbCtD
Letrozole—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0598	0.219	CbGbCtD
Letrozole—CYP3A4—Vincristine—lymphatic system cancer	0.0411	0.151	CbGbCtD
Letrozole—Urticaria—Teniposide—lymphatic system cancer	0.00189	0.0026	CcSEcCtD
Letrozole—Haemorrhage—Carmustine—lymphatic system cancer	0.00188	0.00259	CcSEcCtD
Letrozole—Abdominal pain—Teniposide—lymphatic system cancer	0.00188	0.00259	CcSEcCtD
Letrozole—Body temperature increased—Teniposide—lymphatic system cancer	0.00188	0.00259	CcSEcCtD
Letrozole—Paraesthesia—Fludarabine—lymphatic system cancer	0.00188	0.00258	CcSEcCtD
Letrozole—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00187	0.00258	CcSEcCtD
Letrozole—Sweating—Mitoxantrone—lymphatic system cancer	0.00187	0.00257	CcSEcCtD
Letrozole—Dyspnoea—Fludarabine—lymphatic system cancer	0.00186	0.00256	CcSEcCtD
Letrozole—Oedema peripheral—Carmustine—lymphatic system cancer	0.00186	0.00255	CcSEcCtD
Letrozole—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00185	0.00255	CcSEcCtD
Letrozole—Dyspepsia—Fludarabine—lymphatic system cancer	0.00184	0.00253	CcSEcCtD
Letrozole—Decreased appetite—Fludarabine—lymphatic system cancer	0.00182	0.0025	CcSEcCtD
Letrozole—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.0018	0.00248	CcSEcCtD
Letrozole—Fatigue—Fludarabine—lymphatic system cancer	0.0018	0.00248	CcSEcCtD
Letrozole—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00179	0.00246	CcSEcCtD
Letrozole—Pain—Fludarabine—lymphatic system cancer	0.00179	0.00246	CcSEcCtD
Letrozole—Constipation—Fludarabine—lymphatic system cancer	0.00179	0.00246	CcSEcCtD
Letrozole—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00178	0.00244	CcSEcCtD
Letrozole—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00177	0.00243	CcSEcCtD
Letrozole—Urethral disorder—Vincristine—lymphatic system cancer	0.00176	0.00242	CcSEcCtD
Letrozole—Eye disorder—Carmustine—lymphatic system cancer	0.00176	0.00242	CcSEcCtD
Letrozole—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00176	0.00242	CcSEcCtD
Letrozole—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00175	0.00241	CcSEcCtD
Letrozole—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00175	0.00241	CcSEcCtD
Letrozole—Flushing—Carmustine—lymphatic system cancer	0.00175	0.0024	CcSEcCtD
Letrozole—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00174	0.0024	CcSEcCtD
Letrozole—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.00174	0.00239	CcSEcCtD
Letrozole—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00172	0.00237	CcSEcCtD
Letrozole—Asthenia—Teniposide—lymphatic system cancer	0.00171	0.00235	CcSEcCtD
Letrozole—Malaise—Bleomycin—lymphatic system cancer	0.00169	0.00233	CcSEcCtD
Letrozole—Pruritus—Teniposide—lymphatic system cancer	0.00168	0.00232	CcSEcCtD
Letrozole—Leukopenia—Bleomycin—lymphatic system cancer	0.00168	0.00231	CcSEcCtD
Letrozole—Cardiac disorder—Vincristine—lymphatic system cancer	0.00167	0.0023	CcSEcCtD
Letrozole—Alopecia—Carmustine—lymphatic system cancer	0.00166	0.00229	CcSEcCtD
Letrozole—Body temperature increased—Fludarabine—lymphatic system cancer	0.00165	0.00227	CcSEcCtD
Letrozole—Mental disorder—Carmustine—lymphatic system cancer	0.00165	0.00227	CcSEcCtD
Letrozole—Malnutrition—Carmustine—lymphatic system cancer	0.00164	0.00226	CcSEcCtD
Letrozole—Cough—Bleomycin—lymphatic system cancer	0.00164	0.00225	CcSEcCtD
Letrozole—Angiopathy—Vincristine—lymphatic system cancer	0.00163	0.00224	CcSEcCtD
Letrozole—Diarrhoea—Teniposide—lymphatic system cancer	0.00163	0.00224	CcSEcCtD
Letrozole—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00162	0.00223	CcSEcCtD
Letrozole—Myalgia—Bleomycin—lymphatic system cancer	0.0016	0.0022	CcSEcCtD
Letrozole—Chest pain—Bleomycin—lymphatic system cancer	0.0016	0.0022	CcSEcCtD
Letrozole—Alopecia—Vincristine—lymphatic system cancer	0.00159	0.00219	CcSEcCtD
Letrozole—Back pain—Carmustine—lymphatic system cancer	0.00159	0.00218	CcSEcCtD
Letrozole—Discomfort—Bleomycin—lymphatic system cancer	0.00158	0.00217	CcSEcCtD
Letrozole—Mental disorder—Vincristine—lymphatic system cancer	0.00157	0.00217	CcSEcCtD
Letrozole—Neoplasm—Methotrexate—lymphatic system cancer	0.00157	0.00216	CcSEcCtD
Letrozole—Alopecia—Mitoxantrone—lymphatic system cancer	0.00155	0.00213	CcSEcCtD
Letrozole—Vision blurred—Carmustine—lymphatic system cancer	0.00154	0.00213	CcSEcCtD
Letrozole—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00153	0.00211	CcSEcCtD
Letrozole—Oedema—Bleomycin—lymphatic system cancer	0.00153	0.00211	CcSEcCtD
Letrozole—Infection—Bleomycin—lymphatic system cancer	0.00152	0.0021	CcSEcCtD
Letrozole—Back pain—Vincristine—lymphatic system cancer	0.00151	0.00208	CcSEcCtD
Letrozole—Vomiting—Teniposide—lymphatic system cancer	0.00151	0.00208	CcSEcCtD
Letrozole—Asthenia—Fludarabine—lymphatic system cancer	0.0015	0.00206	CcSEcCtD
Letrozole—Rash—Teniposide—lymphatic system cancer	0.0015	0.00206	CcSEcCtD
Letrozole—Dermatitis—Teniposide—lymphatic system cancer	0.0015	0.00206	CcSEcCtD
Letrozole—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00149	0.00205	CcSEcCtD
Letrozole—Headache—Teniposide—lymphatic system cancer	0.00149	0.00205	CcSEcCtD
Letrozole—Pruritus—Fludarabine—lymphatic system cancer	0.00148	0.00204	CcSEcCtD
Letrozole—Back pain—Mitoxantrone—lymphatic system cancer	0.00147	0.00203	CcSEcCtD
Letrozole—Leukopenia—Carmustine—lymphatic system cancer	0.00147	0.00202	CcSEcCtD
Letrozole—Anorexia—Bleomycin—lymphatic system cancer	0.00146	0.00201	CcSEcCtD
Letrozole—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00146	0.002	CcSEcCtD
Letrozole—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00144	0.00198	CcSEcCtD
Letrozole—Diarrhoea—Fludarabine—lymphatic system cancer	0.00143	0.00197	CcSEcCtD
Letrozole—Hypertension—Carmustine—lymphatic system cancer	0.00142	0.00195	CcSEcCtD
Letrozole—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00141	0.00195	CcSEcCtD
Letrozole—Nausea—Teniposide—lymphatic system cancer	0.00141	0.00194	CcSEcCtD
Letrozole—Vertigo—Vincristine—lymphatic system cancer	0.00141	0.00193	CcSEcCtD
Letrozole—Leukopenia—Vincristine—lymphatic system cancer	0.0014	0.00193	CcSEcCtD
Letrozole—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.0014	0.00192	CcSEcCtD
Letrozole—Myalgia—Carmustine—lymphatic system cancer	0.0014	0.00192	CcSEcCtD
Letrozole—Chest pain—Carmustine—lymphatic system cancer	0.0014	0.00192	CcSEcCtD
Letrozole—Anxiety—Carmustine—lymphatic system cancer	0.00139	0.00191	CcSEcCtD
Letrozole—Paraesthesia—Bleomycin—lymphatic system cancer	0.00138	0.00189	CcSEcCtD
Letrozole—Malaise—Mitoxantrone—lymphatic system cancer	0.00137	0.00189	CcSEcCtD
Letrozole—Dyspnoea—Bleomycin—lymphatic system cancer	0.00137	0.00188	CcSEcCtD
Letrozole—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00136	0.00188	CcSEcCtD
Letrozole—Hypertension—Vincristine—lymphatic system cancer	0.00135	0.00186	CcSEcCtD
Letrozole—Oedema—Carmustine—lymphatic system cancer	0.00134	0.00184	CcSEcCtD
Letrozole—Decreased appetite—Bleomycin—lymphatic system cancer	0.00133	0.00183	CcSEcCtD
Letrozole—Myalgia—Vincristine—lymphatic system cancer	0.00133	0.00183	CcSEcCtD
Letrozole—Cough—Mitoxantrone—lymphatic system cancer	0.00133	0.00183	CcSEcCtD
Letrozole—Infection—Carmustine—lymphatic system cancer	0.00133	0.00183	CcSEcCtD
Letrozole—Vomiting—Fludarabine—lymphatic system cancer	0.00133	0.00183	CcSEcCtD
Letrozole—Rash—Fludarabine—lymphatic system cancer	0.00132	0.00181	CcSEcCtD
Letrozole—Dermatitis—Fludarabine—lymphatic system cancer	0.00132	0.00181	CcSEcCtD
Letrozole—Hypertension—Mitoxantrone—lymphatic system cancer	0.00132	0.00181	CcSEcCtD
Letrozole—Pain—Bleomycin—lymphatic system cancer	0.00131	0.0018	CcSEcCtD
Letrozole—Headache—Fludarabine—lymphatic system cancer	0.00131	0.0018	CcSEcCtD
Letrozole—Tachycardia—Carmustine—lymphatic system cancer	0.00131	0.0018	CcSEcCtD
Letrozole—Arthralgia—Mitoxantrone—lymphatic system cancer	0.0013	0.00179	CcSEcCtD
Letrozole—Myalgia—Mitoxantrone—lymphatic system cancer	0.0013	0.00179	CcSEcCtD
Letrozole—Chest pain—Mitoxantrone—lymphatic system cancer	0.0013	0.00179	CcSEcCtD
Letrozole—Anxiety—Mitoxantrone—lymphatic system cancer	0.00129	0.00178	CcSEcCtD
Letrozole—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00129	0.00177	CcSEcCtD
Letrozole—Lethargy—Methotrexate—lymphatic system cancer	0.00129	0.00177	CcSEcCtD
Letrozole—Discomfort—Mitoxantrone—lymphatic system cancer	0.00128	0.00176	CcSEcCtD
Letrozole—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00128	0.00176	CcSEcCtD
Letrozole—Oedema—Vincristine—lymphatic system cancer	0.00128	0.00176	CcSEcCtD
Letrozole—Anorexia—Carmustine—lymphatic system cancer	0.00128	0.00175	CcSEcCtD
Letrozole—Infection—Vincristine—lymphatic system cancer	0.00127	0.00175	CcSEcCtD
Letrozole—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00126	0.00174	CcSEcCtD
Letrozole—Nervous system disorder—Vincristine—lymphatic system cancer	0.00125	0.00172	CcSEcCtD
Letrozole—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00124	0.00171	CcSEcCtD
Letrozole—Oedema—Mitoxantrone—lymphatic system cancer	0.00124	0.00171	CcSEcCtD
Letrozole—Nausea—Fludarabine—lymphatic system cancer	0.00124	0.00171	CcSEcCtD
Letrozole—Infection—Mitoxantrone—lymphatic system cancer	0.00124	0.0017	CcSEcCtD
Letrozole—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00123	0.0017	CcSEcCtD
Letrozole—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00122	0.00168	CcSEcCtD
Letrozole—Urticaria—Bleomycin—lymphatic system cancer	0.00122	0.00168	CcSEcCtD
Letrozole—Anorexia—Vincristine—lymphatic system cancer	0.00122	0.00168	CcSEcCtD
Letrozole—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00121	0.00167	CcSEcCtD
Letrozole—Body temperature increased—Bleomycin—lymphatic system cancer	0.00121	0.00167	CcSEcCtD
Letrozole—Insomnia—Carmustine—lymphatic system cancer	0.00121	0.00167	CcSEcCtD
Letrozole—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00121	0.00166	CcSEcCtD
Letrozole—Irritability—Methotrexate—lymphatic system cancer	0.0012	0.00166	CcSEcCtD
Letrozole—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.0012	0.00165	CcSEcCtD
Letrozole—Paraesthesia—Carmustine—lymphatic system cancer	0.0012	0.00165	CcSEcCtD
Letrozole—Dyspnoea—Carmustine—lymphatic system cancer	0.00119	0.00164	CcSEcCtD
Letrozole—Somnolence—Carmustine—lymphatic system cancer	0.00119	0.00164	CcSEcCtD
Letrozole—Anorexia—Mitoxantrone—lymphatic system cancer	0.00119	0.00163	CcSEcCtD
Letrozole—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00116	0.0016	CcSEcCtD
Letrozole—Decreased appetite—Carmustine—lymphatic system cancer	0.00116	0.0016	CcSEcCtD
Letrozole—Insomnia—Vincristine—lymphatic system cancer	0.00116	0.00159	CcSEcCtD
Letrozole—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00116	0.00159	CcSEcCtD
Letrozole—Paraesthesia—Vincristine—lymphatic system cancer	0.00115	0.00158	CcSEcCtD
Letrozole—Pain—Carmustine—lymphatic system cancer	0.00114	0.00157	CcSEcCtD
Letrozole—Constipation—Carmustine—lymphatic system cancer	0.00114	0.00157	CcSEcCtD
Letrozole—Breast disorder—Methotrexate—lymphatic system cancer	0.00114	0.00157	CcSEcCtD
Letrozole—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00114	0.00156	CcSEcCtD
Letrozole—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00113	0.00156	CcSEcCtD
Letrozole—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00112	0.00154	CcSEcCtD
Letrozole—Decreased appetite—Vincristine—lymphatic system cancer	0.00111	0.00153	CcSEcCtD
Letrozole—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00111	0.00153	CcSEcCtD
Letrozole—Somnolence—Mitoxantrone—lymphatic system cancer	0.00111	0.00152	CcSEcCtD
Letrozole—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.0011	0.00152	CcSEcCtD
Letrozole—Feeling abnormal—Carmustine—lymphatic system cancer	0.0011	0.00152	CcSEcCtD
Letrozole—Fatigue—Vincristine—lymphatic system cancer	0.0011	0.00152	CcSEcCtD
Letrozole—Asthenia—Bleomycin—lymphatic system cancer	0.0011	0.00151	CcSEcCtD
Letrozole—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00109	0.00151	CcSEcCtD
Letrozole—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00109	0.00151	CcSEcCtD
Letrozole—Pain—Vincristine—lymphatic system cancer	0.00109	0.0015	CcSEcCtD
Letrozole—Constipation—Vincristine—lymphatic system cancer	0.00109	0.0015	CcSEcCtD
Letrozole—Pruritus—Bleomycin—lymphatic system cancer	0.00108	0.00149	CcSEcCtD
Letrozole—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00108	0.00149	CcSEcCtD
Letrozole—Fatigue—Mitoxantrone—lymphatic system cancer	0.00107	0.00148	CcSEcCtD
Letrozole—Constipation—Mitoxantrone—lymphatic system cancer	0.00106	0.00146	CcSEcCtD
Letrozole—Pain—Mitoxantrone—lymphatic system cancer	0.00106	0.00146	CcSEcCtD
Letrozole—Body temperature increased—Carmustine—lymphatic system cancer	0.00106	0.00146	CcSEcCtD
Letrozole—Abdominal pain—Carmustine—lymphatic system cancer	0.00106	0.00146	CcSEcCtD
Letrozole—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00104	0.00144	CcSEcCtD
Letrozole—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00102	0.00141	CcSEcCtD
Letrozole—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00102	0.0014	CcSEcCtD
Letrozole—Abdominal pain—Vincristine—lymphatic system cancer	0.00101	0.00139	CcSEcCtD
Letrozole—Body temperature increased—Vincristine—lymphatic system cancer	0.00101	0.00139	CcSEcCtD
Letrozole—Urticaria—Mitoxantrone—lymphatic system cancer	0.000988	0.00136	CcSEcCtD
Letrozole—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000983	0.00135	CcSEcCtD
Letrozole—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000983	0.00135	CcSEcCtD
Letrozole—Vomiting—Bleomycin—lymphatic system cancer	0.000974	0.00134	CcSEcCtD
Letrozole—Infestation NOS—Methotrexate—lymphatic system cancer	0.000972	0.00134	CcSEcCtD
Letrozole—Infestation—Methotrexate—lymphatic system cancer	0.000972	0.00134	CcSEcCtD
Letrozole—Depression—Methotrexate—lymphatic system cancer	0.000969	0.00133	CcSEcCtD
Letrozole—Rash—Bleomycin—lymphatic system cancer	0.000966	0.00133	CcSEcCtD
Letrozole—Dermatitis—Bleomycin—lymphatic system cancer	0.000965	0.00133	CcSEcCtD
Letrozole—Asthenia—Carmustine—lymphatic system cancer	0.00096	0.00132	CcSEcCtD
Letrozole—Stomatitis—Methotrexate—lymphatic system cancer	0.000947	0.0013	CcSEcCtD
Letrozole—Sweating—Methotrexate—lymphatic system cancer	0.000931	0.00128	CcSEcCtD
Letrozole—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000919	0.00126	CcSEcCtD
Letrozole—Asthenia—Vincristine—lymphatic system cancer	0.000916	0.00126	CcSEcCtD
Letrozole—Diarrhoea—Carmustine—lymphatic system cancer	0.000915	0.00126	CcSEcCtD
Letrozole—Nausea—Bleomycin—lymphatic system cancer	0.00091	0.00125	CcSEcCtD
Letrozole—Asthenia—Mitoxantrone—lymphatic system cancer	0.000892	0.00123	CcSEcCtD
Letrozole—Dizziness—Carmustine—lymphatic system cancer	0.000885	0.00122	CcSEcCtD
Letrozole—Haemoglobin—Methotrexate—lymphatic system cancer	0.000877	0.00121	CcSEcCtD
Letrozole—Diarrhoea—Vincristine—lymphatic system cancer	0.000874	0.0012	CcSEcCtD
Letrozole—Haemorrhage—Methotrexate—lymphatic system cancer	0.000872	0.0012	CcSEcCtD
Letrozole—Hepatitis—Methotrexate—lymphatic system cancer	0.000872	0.0012	CcSEcCtD
Letrozole—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000861	0.00119	CcSEcCtD
Letrozole—Urethral disorder—Methotrexate—lymphatic system cancer	0.000855	0.00118	CcSEcCtD
Letrozole—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000851	0.00117	CcSEcCtD
Letrozole—Vomiting—Carmustine—lymphatic system cancer	0.000851	0.00117	CcSEcCtD
Letrozole—Dizziness—Vincristine—lymphatic system cancer	0.000845	0.00116	CcSEcCtD
Letrozole—Rash—Carmustine—lymphatic system cancer	0.000844	0.00116	CcSEcCtD
Letrozole—Dermatitis—Carmustine—lymphatic system cancer	0.000843	0.00116	CcSEcCtD
Letrozole—Headache—Carmustine—lymphatic system cancer	0.000838	0.00115	CcSEcCtD
Letrozole—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000825	0.00113	CcSEcCtD
Letrozole—Eye disorder—Methotrexate—lymphatic system cancer	0.000815	0.00112	CcSEcCtD
Letrozole—Vomiting—Vincristine—lymphatic system cancer	0.000812	0.00112	CcSEcCtD
Letrozole—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000809	0.00111	CcSEcCtD
Letrozole—Rash—Vincristine—lymphatic system cancer	0.000805	0.00111	CcSEcCtD
Letrozole—Dermatitis—Vincristine—lymphatic system cancer	0.000804	0.00111	CcSEcCtD
Letrozole—Headache—Vincristine—lymphatic system cancer	0.0008	0.0011	CcSEcCtD
Letrozole—Nausea—Carmustine—lymphatic system cancer	0.000795	0.00109	CcSEcCtD
Letrozole—Angiopathy—Methotrexate—lymphatic system cancer	0.000791	0.00109	CcSEcCtD
Letrozole—Vomiting—Mitoxantrone—lymphatic system cancer	0.000791	0.00109	CcSEcCtD
Letrozole—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000786	0.00108	CcSEcCtD
Letrozole—Rash—Mitoxantrone—lymphatic system cancer	0.000784	0.00108	CcSEcCtD
Letrozole—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000783	0.00108	CcSEcCtD
Letrozole—Headache—Mitoxantrone—lymphatic system cancer	0.000779	0.00107	CcSEcCtD
Letrozole—Alopecia—Methotrexate—lymphatic system cancer	0.000771	0.00106	CcSEcCtD
Letrozole—Mental disorder—Methotrexate—lymphatic system cancer	0.000764	0.00105	CcSEcCtD
Letrozole—Malnutrition—Methotrexate—lymphatic system cancer	0.000759	0.00104	CcSEcCtD
Letrozole—Nausea—Vincristine—lymphatic system cancer	0.000759	0.00104	CcSEcCtD
Letrozole—Dysgeusia—Methotrexate—lymphatic system cancer	0.000744	0.00102	CcSEcCtD
Letrozole—Nausea—Mitoxantrone—lymphatic system cancer	0.000739	0.00102	CcSEcCtD
Letrozole—Back pain—Methotrexate—lymphatic system cancer	0.000734	0.00101	CcSEcCtD
Letrozole—Vision blurred—Methotrexate—lymphatic system cancer	0.000716	0.000985	CcSEcCtD
Letrozole—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000704	0.000969	CcSEcCtD
Letrozole—Malaise—Methotrexate—lymphatic system cancer	0.000685	0.000942	CcSEcCtD
Letrozole—Vertigo—Methotrexate—lymphatic system cancer	0.000682	0.000939	CcSEcCtD
Letrozole—Leukopenia—Methotrexate—lymphatic system cancer	0.00068	0.000935	CcSEcCtD
Letrozole—Cough—Methotrexate—lymphatic system cancer	0.000663	0.000912	CcSEcCtD
Letrozole—Arthralgia—Methotrexate—lymphatic system cancer	0.000646	0.000889	CcSEcCtD
Letrozole—Myalgia—Methotrexate—lymphatic system cancer	0.000646	0.000889	CcSEcCtD
Letrozole—Chest pain—Methotrexate—lymphatic system cancer	0.000646	0.000889	CcSEcCtD
Letrozole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000642	0.000883	CcSEcCtD
Letrozole—Discomfort—Methotrexate—lymphatic system cancer	0.000639	0.000879	CcSEcCtD
Letrozole—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00062	0.000853	CcSEcCtD
Letrozole—Infection—Methotrexate—lymphatic system cancer	0.000616	0.000847	CcSEcCtD
Letrozole—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000608	0.000836	CcSEcCtD
Letrozole—Skin disorder—Methotrexate—lymphatic system cancer	0.000602	0.000828	CcSEcCtD
Letrozole—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000599	0.000824	CcSEcCtD
Letrozole—Anorexia—Methotrexate—lymphatic system cancer	0.000591	0.000813	CcSEcCtD
Letrozole—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000565	0.000777	CcSEcCtD
Letrozole—Insomnia—Methotrexate—lymphatic system cancer	0.00056	0.000771	CcSEcCtD
Letrozole—Paraesthesia—Methotrexate—lymphatic system cancer	0.000556	0.000766	CcSEcCtD
Letrozole—Dyspnoea—Methotrexate—lymphatic system cancer	0.000552	0.00076	CcSEcCtD
Letrozole—Somnolence—Methotrexate—lymphatic system cancer	0.000551	0.000758	CcSEcCtD
Letrozole—Dyspepsia—Methotrexate—lymphatic system cancer	0.000545	0.000751	CcSEcCtD
Letrozole—Decreased appetite—Methotrexate—lymphatic system cancer	0.000539	0.000741	CcSEcCtD
Letrozole—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000535	0.000736	CcSEcCtD
Letrozole—Fatigue—Methotrexate—lymphatic system cancer	0.000534	0.000735	CcSEcCtD
Letrozole—Pain—Methotrexate—lymphatic system cancer	0.00053	0.000729	CcSEcCtD
Letrozole—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000511	0.000703	CcSEcCtD
Letrozole—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000507	0.000697	CcSEcCtD
Letrozole—Urticaria—Methotrexate—lymphatic system cancer	0.000492	0.000677	CcSEcCtD
Letrozole—Body temperature increased—Methotrexate—lymphatic system cancer	0.00049	0.000674	CcSEcCtD
Letrozole—Abdominal pain—Methotrexate—lymphatic system cancer	0.00049	0.000674	CcSEcCtD
Letrozole—Asthenia—Methotrexate—lymphatic system cancer	0.000445	0.000612	CcSEcCtD
Letrozole—Pruritus—Methotrexate—lymphatic system cancer	0.000438	0.000603	CcSEcCtD
Letrozole—Diarrhoea—Methotrexate—lymphatic system cancer	0.000424	0.000583	CcSEcCtD
Letrozole—Dizziness—Methotrexate—lymphatic system cancer	0.00041	0.000564	CcSEcCtD
Letrozole—Vomiting—Methotrexate—lymphatic system cancer	0.000394	0.000542	CcSEcCtD
Letrozole—Rash—Methotrexate—lymphatic system cancer	0.000391	0.000538	CcSEcCtD
Letrozole—Dermatitis—Methotrexate—lymphatic system cancer	0.00039	0.000537	CcSEcCtD
Letrozole—Headache—Methotrexate—lymphatic system cancer	0.000388	0.000534	CcSEcCtD
Letrozole—Nausea—Methotrexate—lymphatic system cancer	0.000368	0.000506	CcSEcCtD
